Lutz Jacobasch
Overview
Explore the profile of Lutz Jacobasch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Laubach J, Schjesvold F, Mariz M, Dimopoulos M, Lech-Maranda E, Spicka I, et al.
Lancet Oncol
. 2020 Dec;
22(1):142-154.
PMID: 33301738
Background: Improved therapeutic options are needed for patients with relapsed or relapsed and refractory multiple myeloma. Subcutaneous bortezomib has replaced intravenous bortezomib as it is associated with a more favourable...
12.
Al-Batran S, Hofheinz R, Reichart A, Pauligk C, Schonherr C, Schlag R, et al.
Int J Cancer
. 2020 Oct;
148(6):1478-1488.
PMID: 33038277
Few data exist on health-related quality of life (QoL) in patients with metastatic pancreatic cancer (mPC) receiving first-line chemotherapy (Awad L ZE, Mesbah M Boston, MA. Applying survival data methodology...
13.
Tintelnot J, Goekkurt E, Binder M, Thuss-Patience P, Lorenzen S, Riera Knorrenschild J, et al.
BMC Cancer
. 2020 Jun;
20(1):503.
PMID: 32487035
Background: Esophagogastric adenocarcinoma (EGA) currently represents a main cause of cancer related death. Despite an intensified treatment for locally advanced or metastatic EGA with a doublet chemotherapy consisting of a...
14.
Fokas E, Allgauer M, Polat B, Klautke G, Grabenbauer G, Fietkau R, et al.
J Clin Oncol
. 2019 Jun;
37(34):3212-3222.
PMID: 31150315
Purpose: Total neoadjuvant therapy is a new paradigm for rectal cancer treatment. Optimal scheduling of preoperative chemoradiotherapy (CRT) and chemotherapy remains to be established. Patients And Methods: We conducted a...
15.
Gattermann N, Coll R, Jacobasch L, Allameddine A, Azmon A, DeBonnett L, et al.
Eur J Haematol
. 2018 May;
PMID: 29777631
Objectives: Erythropoiesis-stimulating agents (ESAs) remain first-choice to treat symptomatic anemia and delay transfusion dependence in most patients with lower-risk myelodysplastic syndromes (MDS) without del(5q). Deferasirox increased erythroid responses in some...
16.
Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, et al.
J Clin Oncol
. 2017 Aug;
35(29):3330-3337.
PMID: 28817370
Purpose Gemcitabine is standard of care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC). The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with gemcitabine has...
17.
Thiery-Vuillemin A, Theodore C, Jacobasch L, Schmitz J, Papandreou C, Guillot A, et al.
Clin Genitourin Cancer
. 2014 Dec;
13(3):231-8.
PMID: 25456838
Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor. It gained approval based on the results of the RECORD-1 (Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous...